Plain-English translation of NCT05435248 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is designed as an oral pill to treat advanced non-small-cell lung cancer — particularly in patients whose cancer has a specific genetic change called EGFR C797S. The study will evaluate whether this medication is safe and effective, and what dose works best for patients whose cancer has stopped responding to standard treatments.
Many patients with advanced lung cancer develop resistance to existing treatments, especially when their cancer has certain genetic mutations. This trial is exploring whether this new medication could offer hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take this medication by mouth as a pill. The trial has three phases: first, researchers will test increasing doses to find the safest level; second, they may expand the study with more patients at that dose; and third, they will test how well the medication works in a larger group of patients. You will have regular visits to your doctor for blood tests, scans, and check-ins to monitor how you're responding and track any side effects. The total duration depends on which phase you enter and how well you respond to treatment.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Enrollment target
~354 participants
Started
March 2022
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Li Zhang, Master
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.